Literature DB >> 29745356

Noninfectious Hospital Adverse Events Decline After Elimination of Contact Precautions for MRSA and VRE.

Elise M Martin1, Brandy Bryant2, Tristan R Grogan3, Zachary A Rubin1, Dana L Russell4, David Elashoff3, Daniel Z Uslan1.   

Abstract

OBJECTIVETo evaluate the impact of discontinuing routine contact precautions (CP) for endemic methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) on hospital adverse events.DESIGNRetrospective, nonrandomized, observational, quasi-experimental study.SETTINGAcademic medical center with single-occupancy rooms.PARTICIPANTSInpatients.METHODSWe compared hospital reportable adverse events 1 year before and 1 year after discontinuation of routine CP for endemic MRSA and VRE (preintervention and postintervention periods, respectively). Throughout the preintervention period, daily chlorhexidine gluconate bathing was expanded to nearly all inpatients. Chart reviews were performed to identify which patients and events were associated with CP for MRSA/VRE in the preintervention period as well as the patients that would have met prior criteria for MRSA/VRE CP but were not isolated in the postintervention period. Adverse events during the 2 periods were compared using segmented and mixed-effects Poisson regression models.RESULTSThere were 24,732 admissions in the preintervention period and 25,536 in the postintervention period. Noninfectious adverse events (ie, postoperative respiratory failure, hemorrhage/hematoma, thrombosis, wound dehiscence, pressure ulcers, and falls or trauma) decreased by 19% (12.3 to 10.0 per 1,000 admissions, P=.022) from the preintervention to the postintervention period. There was no significant difference in the rate of infectious adverse events after CP discontinuation (20.7 to 19.4 per 1,000 admissions, P=.33). Patients with MRSA/VRE showed the largest reduction in noninfectious adverse events after CP discontinuation, with a 72% reduction (21.4 to 6.08 per 1,000 MRSA/VRE admissions; P<.001).CONCLUSIONAfter discontinuing routine CP for endemic MRSA/VRE, the rate of noninfectious adverse events declined, especially in patients who no longer required isolation. This suggests that elimination of CP may substantially reduce noninfectious adverse events.Infect Control Hosp Epidemiol 2018;788-796.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29745356      PMCID: PMC6677236          DOI: 10.1017/ice.2018.93

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  11 in total

Review 1.  Vancomycin-resistant enterococci (VRE): a reason to isolate?

Authors:  Maria J G T Vehreschild; Miriam Haverkamp; Lena M Biehl; Sebastian Lemmen; Gerd Fätkenheuer
Journal:  Infection       Date:  2018-09-03       Impact factor: 3.553

2.  Implementation of a Clostridioides difficile prevention bundle: Understanding common, unique, and conflicting work system barriers and facilitators for subprocess design.

Authors:  Jackson S Musuuza; Ann Schoofs Hundt; Pascale Carayon; Karly Christensen; Caitlyn Ngam; Nicholas Haun; Nasia Safdar
Journal:  Infect Control Hosp Epidemiol       Date:  2019-06-13       Impact factor: 3.254

3.  Predicting probability of perirectal colonization with carbapenem-resistant Enterobacteriaceae (CRE) and other carbapenem-resistant organisms (CROs) at hospital unit admission.

Authors:  Katherine E Goodman; Patricia J Simner; Eili Y Klein; Abida Q Kazmi; Avinash Gadala; Matthew F Toerper; Scott Levin; Pranita D Tamma; Clare Rock; Sara E Cosgrove; Lisa L Maragakis; Aaron M Milstone
Journal:  Infect Control Hosp Epidemiol       Date:  2019-03-27       Impact factor: 3.254

4.  Recommendations for change in infection prevention programs and practice.

Authors:  Robert Garcia; Sue Barnes; Roy Boukidjian; Linda Kaye Goss; Maureen Spencer; Edward J Septimus; Marc-Oliver Wright; Shannon Munro; Sara M Reese; Mohamad G Fakih; Charles E Edmiston; Martin Levesque
Journal:  Am J Infect Control       Date:  2022-05-04       Impact factor: 4.303

Review 5.  Barrier Precautions in the Era of Multidrug Pathogens.

Authors:  Rachel Pryor; Carli Viola-Luqa; Olivia Hess; Gonzalo Bearman
Journal:  Curr Treat Options Infect Dis       Date:  2020-06-29

6.  Risk Factors for Long-Term Vancomycin-Resistant Enterococci Persistence-A Prospective Longitudinal Study.

Authors:  Carlos L Correa-Martinez; Verena B Stollenwerk; Annelene Kossow; Frieder Schaumburg; Alexander Mellmann; Stefanie Kampmeier
Journal:  Microorganisms       Date:  2019-09-26

7.  Does vancomycin resistance increase mortality in Enterococcus faecium bacteraemia after orthotopic liver transplantation? A retrospective study.

Authors:  S Dubler; M Lenz; S Zimmermann; D C Richter; K H Weiss; A Mehrabi; M Mieth; T Bruckner; M A Weigand; T Brenner; A Heininger
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-31       Impact factor: 4.887

8.  Evaluation of Patients' Adverse Events During Contact Isolation for Vancomycin-Resistant Enterococci Using a Matched Cohort Study With Propensity Score.

Authors:  JaHyun Kang; Eunjeong Ji; Junghee Kim; Hyunok Bae; Eunyoung Cho; Eu Suk Kim; Myoung Jin Shin; Hong Bin Kim
Journal:  JAMA Netw Open       Date:  2022-03-01

9.  Higher incidence of adverse events in isolated patients compared with non-isolated patients: a cohort study.

Authors:  Fátima Jiménez-Pericás; María Teresa Gea Velázquez de Castro; María Pastor-Valero; Carlos Aibar Remón; Juan José Miralles; María Del Carmen Meyer García; Jesús Maria Aranaz Andrés
Journal:  BMJ Open       Date:  2020-10-26       Impact factor: 2.692

10.  Digestive Decolonization of Colorectal Carriage of Vancomycin-resistant Enterococcus faecium in a Japanese Adult.

Authors:  Shunsuke Uno; Yaoko Takano; Osamu Iketani; Tomohiro Abiko; Tomoru Miwa; Kosaku Nanki; Tomohiro Kurihara; Yuko Tamura; Miyuki Ara; Yoshifumi Uwamino; Masayoshi Shinjoh; Takehiko Mori; Naoki Hasegawa
Journal:  Intern Med       Date:  2021-06-26       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.